About: COVID-19 pandemic: an overview of epidemiology, parthenogenesis, diagnostics and potential vaccines and therapeutics

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 pandemic: an overview of epidemiology, parthenogenesis, diagnostics and potential vaccines and therapeutics Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	COVID-19 pandemic: an overview of epidemiology, parthenogenesis, diagnostics and potential vaccines and therapeutics
Creator	Dua, Kamal Aljabali, Alaa Amawi, Haneen Deiab, Ghina'a I, Abu Murtaza, & Tambuwala, M
source	Medline; PMC; WHO
abstract	At the time of writing this review, severe acute respiratory coronavirus syndrome-2 (SARS-CoV-2) has infected more than 2,355,853 patients and resulted in more than 164,656 deaths worldwide (as of 20 April 2020). This review highlights the preventive measures, available clinical therapies and the potential of vaccine development against SARS-CoV-2 by taking into consideration the strong genetic similarities of the 2003 epidemic SARS-CoV. Recent studies are investigating the repurposing of US FDA-approved drugs as there is no available vaccine yet with many attempts under clinical evaluation. Several antivirals, antimalarials and immunomodulators that have shown activity against SARS-CoV and Middle East coronavirus respiratory syndromes are being evaluated. In particular, hydroxychloroquine, remdesivir, favipiravir, arbidol, tocilizumab and bevacizumab have shown promising results. The main aim of this review is to provide an overview of this pandemic and where we currently stand.
has issue date	2020-05-13(xsd:dateTime)
bibo:doi	10.4155/tde-2020-0035
bibo:pmid	32397911
has license	cc-by
sha1sum (hex)	26cc6d2fe10f39424d2106109fd50eec6a5136d1
schema:url	https://doi.org/10.4155/tde-2020-0035
resource representing a document's title	COVID-19 pandemic: an overview of epidemiology, parthenogenesis, diagnostics and potential vaccines and therapeutics
has PubMed Central identifier	PMC7222554
has PubMed identifier	32397911
schema:publication	Therapeutic delivery
resource representing a document's body	covid:26cc6d2fe10f39424d2106109fd50eec6a5136d1#body_text
is schema:about of	named entity 'APRIL' named entity 'MAIN' named entity 'STRONG' named entity 'Middle East' named entity 'SARS-CoV' named entity 'vaccine' named entity 'antimalarials' named entity 'favipiravir' named entity 'vaccine' named entity 'Bevacizumab' named entity 'nucleocapsid' named entity 'China' named entity 'intravenously' named entity 'pneumonia' named entity 'acute respiratory distress syndrome' named entity 'Ebola' named entity 'vaccine' named entity 'ibuprofen' named entity 'viruses' named entity 'interferon' named entity 'extracorporeal membrane oxygenation' named entity 'angiogenesis' named entity 'TCM' named entity 'methylprednisolone' named entity 'upregulation' named entity 'SARS-CoV-2' named entity 'intracellular' named entity 'antiviral therapy' named entity 'infection' named entity 'SARS-CoV-2' named entity 'preventive therapy' named entity 'TCM' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'effector proteins' named entity 'corticosteroids' named entity 'SARS-CoV-2' named entity 'clinical trial' named entity 'comorbidity' named entity 'SARS-CoV-2 outbreak' named entity 'mechanical ventilation' named entity 'SARS-CoV-2' named entity 'cytotoxicity' named entity 'SARS-CoV' named entity 'ribavirin' named entity 'clinical trials' named entity 'pneumonia' named entity 'proteases' named entity 'survival time' named entity 'liver' named entity 'infection' named entity 'dyspnea' named entity 'Sars' named entity 'clinical research center' named entity 'clinical trials' named entity 'lung infections' named entity 'International Health Regulations' named entity 'oxygen' named entity 'azithromycin' named entity 'antibodies' named entity 'nucleocapsid' named entity 'nausea' named entity 'high-quality' named entity 'sepsis' named entity 'WHO' named entity 'plasma half-life' named entity 'protein' named entity 'real-time RT-PCR' named entity 'SARS-CoV-2' named entity 'antibody' named entity 'contaminated areas' named entity 'antibodies' named entity 'Italy' named entity 'acute respiratory distress syndrome' named entity 'LPV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software